Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Aug 27, 2020
|
staff reporter

NEW YORK – Share prices for several diagnostic companies declined sharply on Thursday after Abbott Laboratories and the US Food and Drug Administration announced that the firm had received Emergency Use Authorization for a rapid, low-cost SARS-CoV-2 antigen test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Areas of Limited Testing

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Clouded 'Crystal Ball'

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

Science Papers Trace Drivers of Metastasis; Genetic Analysis of Stone, Bronze Age Eastern Europeans

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

What's Popular?

In Business News

  1. Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

  2. Lucira Health Files for $115M IPO

  3. Ancestry Shutters Health Offering, Raising Questions About Future of Consumer Genomics

    Premium

  4. Invitae Prices $400M Common Stock Offering

  5. Invitae to Raise $400M in Proposed Public Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.